linus pauling institute glutathione A Vision for the Future of the LINUS PAULING INSTITUTE
Description
Atalay, L
S.AndradeM
The current treatment for ovarian cancer is liable to develop chemotherapy resistance and high recurrence rate, in which a new strategy is demanded
The incidence of adverse events in the Cx601 group was 76.7%, whereas it was 72.5% in the control group
Rohatgi PR, Swisher SG , Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA
members of the heteromeric amino acid transporters (HAT) family) to the cell surface 28,29,30
